Good MorningEquity markets tried to rebound from Wednesday's unexpected selloff on Thursday but failed to regain the prior days' losses. The S&P gained 1% for the day but closed well off the highs for the week. The weekly pattern suggests a rising level of fear ahead of the PCE report, due out Friday. The PCE report is expected to confirm slowing inflation but at an insufficient pace to allow the FOMC to cut interest rates soon.
The S&P 500 price action shows resistance below the all-time high, a critical hurdle for the market. Given the proper catalyst, resistance at this level could lead to range-bound trading or a sharp correction. That catalyst could come soon, given the risk of inflation accelerating. Oil markets are already stabilizing after their correction, and ocean-going freight rates are through the roof on geopolitical concerns centered on the Red Sea. Featured: A Few Quiet Tickers Are Starting to Move — Report Inside (Ad) 
|
Consumer Staples | |
When an economic downturn arrives, many investors focus on the benefits that consumer staples can offer them. As the name suggests, consumer staples are products consumers rely on as "staples" in their daily lives. Household cleaning supplies, toiletries, and food products are all examples of cons... Read the Full Story |
|
From Our Partners | | Tomorrow morning, a small group of investors will receive a text alert tied to what may be the most powerful stock rating software in the world - and every message it has sent has averaged a gain of 310 percent, including the misses.
Members of this exclusive list have seen nearly 3,000 chances to double their money and over 400 chances to 10x it. The next alert goes out as early as 9:30 a.m. | | Learn how to sign up and receive the next alert today |
|
Industrials | |
Looking for new technology to invest in?
Pull up a seat and join the club.
New tech is always a popular and exciting investment idea since groundbreaking tech advancements tend to attract gobs of money. However, tech is a volatile sector, and these companies infrequently experience success on ... Read the Full Story |
|
Retail/Wholesale | |
Like one of its colorful salad bowls, fast-casual restaurant chain CAVA Group Inc. (NYSE: CAVA) has been a mix of green and red since its June 2023 IPO.
The Mediterranean-themed Chipotle challenger ran nearly 60% in its first two months of trading on a healthy investor appetite for new issues. I... Read the Full Story |
|
From Our Partners | | Your account is not currently signed up for MarketBeat's free Monday morning stock ideas. Our team is going to be releasing an important pick on Monday morning (at 11am ET) and we want to make sure that you are able to see it. | | Add your name to the distribution list here |
|
Auto/Tires/Trucks | |
RV stocks have been struggling to regain traction following the social-distancing craze that drove them to record highs. The problems were rising prices and an inventory glut compounded by high interest rates.
Now, data from the RVIAA suggests that industry normalization is at hand, and growth w... Read the Full Story |
|
Technology | |
With just a few days left until Santa comes, shares of Micron Technology Inc (NASDAQ: MU) are set to give investors an early Christmas present. They jumped 5% in last night’s after-hours sessions off the back of the company’s fiscal Q1 earnings, which smashed analyst expectations. It w... Read the Full Story |
|
From Our Partners | | In February 2016, Nvidia was trading at $2.51 split-adjusted - and a specific data pattern had already flagged it before Wall Street caught on.
That same pattern is now pointing at a single company. One analyst is revealing the ticker in a free presentation, available for a limited time. | | Access the free presentation and get the ticker before it closes |
|
Medical | |
Investors who own Pfizer Inc. (NYSE: PFE) may have expected 2023 to be what football teams call a "rebuilding year." The company shifted its focus away from COVID-19 drugs and toward potential deals, share buybacks, and new treatments in its pipeline.
While rebuilding years are often messy, Pfize... Read the Full Story |
|
Retail/Wholesale | | As year-end swiftly approaches, it's time to reflect on the year that was. 2023 will be remembered as the year of not just one standout catalyst but many. Notably the rise of Artificial Intelligence (AI), ongoing geopolitical tensions and conflicts, rising interest rates, and the Federal Reserve's b... Read the Full Story |
|
Markets | |
United States Steel (NYSE: X) was once a more important American company than it is today, having been a Dow component until 1990. But it's back in the headlines after Japan's Nippon Steel Corp. (OTCMKTS: NPSCY) said it would acquire the company for $14.1 billion.
That beat out an earlier bid fro... Read the Full Story |
|
Technology | |
Insiders are selling into the rallies on some widely held stocks, posing a potential headwind for the market. The caveat for investors and short-sellers alike is that this activity is far from bearish. While insider selling can signify impending doom, particularly when ramping up, that is not the ... Read the Full Story |
|
Consumer Discretionary | |
Most stock call option contracts lose money upon expiration. They expire worthless. If you buy an out-of-the-money (OTM) call option because you believe a stock will rise in value, chances are high that you will lose most or all of your investment by options expiration. Options players that take d... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. | | View Today's Stock Pick |
|
